- Approval Id
- e1c96909937583dd
- Drug Approval Emc Name
- Mestinon 60 mg Tablets
- Drug Name
- Mestinon 60 mg Tablets
- Company Address
- Building 4, Trident Place, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL
- Company Website
- http://www.mylan.com
- Company Telephone
- +44 (0)1707 853 000
- Company Medical Info Direct Line
- +44 (0)1707 853 000
- Company Medical Info Email
- info@mylan.co.uk
- Company Customer Care Direct Line
- +44 (0)1707 853 000 select option 2
- Company Medical Info Fax
- +44 (0)1707 261 803
- Company Stock Availability
- +44 (0)1707 853 000 select option 2
- Atc Code
- N07AA02
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Mylan Products Ltd,
Station Close,
Potters Bar,
Hertfordshire,
EN6 1TL,
United Kingdom
- Authorisation Number
- PL 46302/0133
- Instruction Authorisation Holder
- Mylan Products Ltd,
Station Close,
Potters Bar,
Hertfordshire,
EN6 1TL,
United Kingdom
- Instruction Authorisation Number
- PL 46302/0133
- Instruction Composition
- Each tablet contains 60 mg pyridostigmine bromide.
For the full list of excipients, see section 6.1
\*\*Excipients with known effect:\*\*
Lactose: 60.75 mg/ tablet
- Instruction Dosage Form
- Tablet for oral administration.
White to off-white, round, biplanar, bevel-edged tablets imprinted with “ V ” M60 across one face and with two break marks forming a cross on the other.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Myasthenia gravis, paralytic ileus and post-operative urinary retention.4.2 Posology and method of administration
\*\*Posology\*\*
\*Myasthenia gravis\*
\*Adults\*
Doses of 30 to 120mg each are given at intervals throughout the day when maximum strength is needed (for example, on rising and before mealtimes). The usual duration of action of a dose is 3 to 4 hours in the daytime but a longer effect (6 hours) is often obtained with a dose taken on retiring for bed.
The total daily dose is usually in the range of 5 – 20 tablets but doses higher than these doses may be needed by some patients. according to dose titration
\*Paediatric population\*
Children under 6 years old should receive an initial dose of half a tablet (30mg) of Mestinon; children 6 – 12 years old should receive one tablet (60mg). Dosage should be increased gradually, in increments of 15 – 30mg daily, until maximum improvement is obtained. Total daily requirements are usually in the range to 30 – 360mg.
\*Other Indications (paralytic ileus, post-operative urinary retention)\*
\*Adults\*
The usual dose is 1 to 4 tablets (60 – 240mg) per day.
\*Paediatric population\*
The usual dose is 15 – 60mg per day.
The frequency of these doses may be varied according to the needs of the patient.
\*Special populations\*
\*Elderly\*
There are no specific dosage recommendations for Mestinon in elderly patients.
\*Renal impairment\*
Mestinon is mainly excreted unchanged in the urine, therefore lower doses may be required in patients with renal impairment and treatment should be based on titration of drug dosage to effect.
\*Hepatic impairment\*
There are no specific dosage recommendations for Mestinon in patients with hepatic impairment.
\*\*Method of administration\*\*
Mestinon should be taken with water. For oral use.4.3 Contraindications
Mestinon is contra-indicated in patients with:
- Hypersensitivity to the active substance, bromides or to any of the excipients listed in section 6.1.
- Mechanical gastro-intestinal or urinary obstruction4.4 Special warnings and precautions for use
Extreme caution is required when administering Mestinon to patients with obstructive respiratory diseases like bronchial asthma and chronic obstructive pulmonary disease (COPD).
Care must be taken in patients with:
- Arrhythmias such as bradycardia and AV block (elderly patients may be more susceptible to dysrhythmias than the young adult)
- Recent coronary occlusion
- Hypotension,
- Vagotonia
- Peptic ulcer
- Epilepsy or Parkinsonism
- Hyperthyroidism
- Renal impairment
When relatively large doses of Mestinon are taken by myasthenic patients it may be necessary to give atropine or other anticholinergic drugs to specifically counteract the muscarinic effects of Mestinon while maintaining its nicotinergic effect.
In all patients the possibility of "cholinergic crisis", due to overdose of Mestinon, and its differentiation from "myasthenic crisis", due to increased severity of the disease, must be considered. Both types of crisis are manifested by increased muscle weakness, but whereas myasthenic crisis may require more intensive anticholinesterase treatment, cholinergic crisis calls for immediate discontinuation of this treatment and appropriate supportive measures, including respiratory assistance.
The requirement for Mestinon is usually markedly decreased after thymectomy or when additional therapy (steroids, immunosuppressant drugs) is given. (see section 4.5).
Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine.4.5 Interaction with other medicinal products and other forms of interaction
\*Immunosuppressant drugs\*
The requirement for pyridostigmine bromide could be decreased by concomitant use with corticosteroids or immunosuppressant drugs. Nethertheless, a new addition of corticosteroids may initially aggravate the symptoms of myasthenia gravis.
\*\*\*Thymectomy\*\*\*
The need for Mestinon dosing may be decreased after thymectomy. (see section 4.4)
\*Methylcellulose\*
Methylcellulose and medicine containing methylcellulose as excipients can completely inhibit absorption of pyridostigmine bromide.
\*Antimuscarinics\*
Atropine and hyoscine antagonise the muscarinic effects of pyridostigmine bromide and the slower gastro-intestinal motility caused by these drugs may affect the absorption of pyridostigmine.
\*Muscle Relaxants\*
Pyridostigmine antagonises the effect of non-depolarising muscle relaxants (e.g. pancuronium and vecuronium). Pyridostigmine may prolong the effect of depolarising muscle relaxants (e.g. suxamethonium).
\*Others\*
Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission may interact with pyridostigmine bromide.4.6 Fertility, pregnancy and lactation
Fertility
Nonclinical investigations in rats have not shown any negative effects on reproductive behaviour.
Pregnancy
The safety of Mestinon during pregnancy has not been established.
Although the possible hazards to mother and child must be weighed against the potential benefits in every case, experience with Mestinon in pregnant patients with myasthenia gravis has revealed no untoward effect of the drug on the course of pregnancy. As the severity of myasthenia gravis often fluctuates considerably in pregnancy, particular care is required to avoid cholinergic crisis due to overdose. Since pyridostigmine bromide crosses the placenta barrier excessive dose of pyridostigmine should be avoided; the newborn child should be monitored to possible effects.
Reproductive studies in rabbits and rats showed no teratogenic but embryo-/foetotoxic effects at doses toxic to the dam (see section 5.3).
Intravenous application of pyridostigmine can induce contraction of the uterus (especially in the last period of pregnancy).
Lactation
The safety of pyridostigmine during lactation has not been established. Observations indicate that only negligible amounts of pyridostigmine are excreted in breast milk. Nevertheless, due regard should be paid to possible effects on the breast-fed infant.4.7 Effects on ability to drive and use machines
Miosis and accommodation disorders caused by pyridostigmine bromide or an inadequate treatment of Myasthenia gravis, Mestinon may impair visual acuity and consequently the ability to react as well as the ability to drive and use machinery.4.8 Undesirable effects
As with all cholinergic products, Mestinon may have unwanted functional effects on the autonomic nervous system. Muscarine-like adverse effects may be exhibited as nausea, vomiting, diarrhoea, abdominal cramps, increased peristaltic and increased bronchial secretion, salivation, bradycardia and miosis.
The primary nicotinic effects are muscle spasms, fasciculation and muscular weakness.
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000) Very rare (<1/10,000) Not known (cannot be estimated from the available data)
The following undesirable effects were observed whereas the frequency of undesirable effect is not known:
\*\*Immune system disorders\*\*
Frequency not known: Drug hypersensitivity
\*\*Nervous system disorders\*\*
Frequency not known: Syncope
\*\*Eye disorders\*\*
Frequency not known: Miosis, increased lacrimation, accommodation disorders (e.g. blurred vision)
\*\*Cardiac disorders\*\*
Frequency not known: Arrhythmia (including bradycardia, tachycardia, AV block), Prinzmetal angina, as well as syncope and hypotension (see section 4.9)
\*\*Vascular disorders\*\*
Frequency not known: Flushing, hypotension
\*\*Respiratory, thoracic and mediastinal disorders\*\*
Frequency not known: Increased bronchial secretion combined with bronchoconstriction
\*\*Gastrointestinal disorders\*\*
Frequency not known: Nausea, vomiting, diarrhoea, gastrointestinal hypermotility, salivary hypersecretion, abdominal symptoms (e.g. discomfort pain, cramps etc.)
\*\*Skin and subcutaneous tissue disorders\*\*
Frequency not known: Rash (disappears usually soon after ceasing of medication. Bromide containing medicines should no longer be used.) Hyperhidrosis, urticaria
\*\*Musculoskeletal and connective tissue disorders\*\*
Frequency not known: Increased muscle weakness fasciculation, tremors and muscle cramps or muscle hypotonia (see section 4.9)
\*\*Renal and urinary disorders\*\*
Frequency not known: Urinary urgency
Because these symptoms may be an indication of cholinergic crisis, the physician should be notified immediately to clarify the diagnosis (see section 4.9)
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard4.9 Overdose
Overdosage may lead to “cholinergic crisis” characterised by severe muscarinic and nicotinic symptoms of marked muscle weakness. Cardiovascular and respiratory failure may occur.
Mestinon may cause cholinergic crisis. Signs of overdosage due to muscarinic effects may include abdominal cramps, increased peristalsis, diarrhoea, nausea and vomiting, increased bronchial secretions, bronchospasm, salivation, hyperhydrosis and miosis. Nicotinic effects consist of muscular cramps, fasciculations and general weakness up to paralysis.
Hypotension up to cardiovascular collapse, bradyarrhythmia, up to cardiac arrest may occur.
Central nervous system effects may include agitation, confusion, slurred speech, nervousness, irritation, visual hallucinations. Convulsions and coma may occur.
Mestinon treatment must be stopped immediately. Artificial ventilation should be instituted if respiration is severely depressed. Atropine sulphate 1 to 2mg intravenously is an antidote to the muscarinic effects. Doses may be repeated every 5 to 30 minutes as needed.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Nervous system, parasympathomimetics, anticholinesterases, pyridostigmine , ATC code: N07AA02
Pyridostigmine is a reversible cholinesterase inhibitor, which an enzyme inactivates acetylcholine. Pyridostigmine prolongs the acetylcholine effect at the synaptic cleft. It does not cross the blood-brain barrier at non-toxic doses. Pyridostigmine has a more prolonged action than neostigmine although it is somewhat slower to take effect (generally taking 30-60 minutes). Because it has a weaker muscarinic effect than neostigmine it is usually much better tolerated by myasthenic patients, in whom its longer duration of action is also an advantage.5.2 Pharmacokinetic properties
Oral pyridostigmine bromide is poorly absorbed by about 22-25%. The rate and extent of absorption show wide inter-individual differences.
Administered in healthy volunteers at oral daily doses of 120 mg, 120-370 mg, and 180-1440 mg, the oral absolute bioavailability of pyridostigmine bromide was 7.6%, 18.9%, and 3-4% with Cmax of 40-80 μg/L, 20-100 μg/L, and 180 μg/L at tmax of 3-4 h, 1.5-6 h, and 1.5 h, respectively. This low and highly variable bioavailability across studies is attributed to the low absorption rate of pyridostigmine. In patients with myasthenia gravis, oral absolute bioavailability may decrease to 3.3%.
Distribution
Pyridostigmine is not bound to plasma proteins. The apparent volume of distribution after intravenous administration was 1.03 L/kg to 1.43 L/kg in healthy subjects, 1.76 L/kg in myasthenia gravis patients, and 0.53 to 1.1 L/kg in surgical patients.
The concentration of pyridostigmine in breast milk has been found to be 36 to 113% compared to maternal plasma, which implies a very low dose to the nursing infant (about 0.1% of the dose per kilogram bodyweight taken by the mother).
Metabolism
Pyridostigmine is metabolized only to a small extent. It is hydrolised by plasma cholinesterases. The main metabolite of pyridostigmine is the hydrolysis product 3-hydroxy-N-methylpyridinium.
Elimination
Systemic (intravenous) pyridostigmine is mainly excreted by the kidneys (75-90%) as parent compound and as inactive metabolites at a ratio of about 4:1. With oral use, a total of 5-15% of oral doses is dose-dependently excreted by the kidneys as parent compound, thus reflecting the low degree of oral pyridostigmine absorption.
The total plasma clearance was very rapid with 0.65 L/h/kg in healthy subjects, 0.29-1.0 L/h/kg in myasthenic patients, and 0.52-0.98 L/h/kg in surgical patients, respectively.
After intravenous administration, the apparent terminal elimination half-life was 1.51-1.74 h in healthy volunteers, 1.05 h in myasthenic patients, and 0.38-1.86 h in surgical patients, respectively. With oral administration, this was 3 to 4 h.5.3 Preclinical safety data
There are no preclinical data of relevance to the prescriber, which are additional to those already included in other sections of the SmPC.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Each tablet contains:
Lactose
Starch
Precipitated Silica
Talc
Magnesium Stearate
Purified Water6.2 Incompatibilities
Not applicable.6.3 Shelf life
3 years.6.4 Special precautions for storage
Store below 25°C. Store in the original package in order to protect from light and moisture.6.5 Nature and contents of container
Amber glass bottles with aluminium screw or low density polyethylene caps and desiccant containing 200 tablets.6.6 Special precautions for disposal and other handling
No special requirements for disposal.
- Instruction Content
- ## Composition
Each tablet contains 60 mg pyridostigmine bromide.
For the full list of excipients, see section 6.1
\*\*Excipients with known effect:\*\*
Lactose: 60.75 mg/ tablet
## Pharmaceutical Form
Tablet for oral administration.
White to off-white, round, biplanar, bevel-edged tablets imprinted with “ V ” M60 across one face and with two break marks forming a cross on the other.
## Clinical Particulars
4.1 Therapeutic indications
Myasthenia gravis, paralytic ileus and post-operative urinary retention.4.2 Posology and method of administration
\*\*Posology\*\*
\*Myasthenia gravis\*
\*Adults\*
Doses of 30 to 120mg each are given at intervals throughout the day when maximum strength is needed (for example, on rising and before mealtimes). The usual duration of action of a dose is 3 to 4 hours in the daytime but a longer effect (6 hours) is often obtained with a dose taken on retiring for bed.
The total daily dose is usually in the range of 5 – 20 tablets but doses higher than these doses may be needed by some patients. according to dose titration
\*Paediatric population\*
Children under 6 years old should receive an initial dose of half a tablet (30mg) of Mestinon; children 6 – 12 years old should receive one tablet (60mg). Dosage should be increased gradually, in increments of 15 – 30mg daily, until maximum improvement is obtained. Total daily requirements are usually in the range to 30 – 360mg.
\*Other Indications (paralytic ileus, post-operative urinary retention)\*
\*Adults\*
The usual dose is 1 to 4 tablets (60 – 240mg) per day.
\*Paediatric population\*
The usual dose is 15 – 60mg per day.
The frequency of these doses may be varied according to the needs of the patient.
\*Special populations\*
\*Elderly\*
There are no specific dosage recommendations for Mestinon in elderly patients.
\*Renal impairment\*
Mestinon is mainly excreted unchanged in the urine, therefore lower doses may be required in patients with renal impairment and treatment should be based on titration of drug dosage to effect.
\*Hepatic impairment\*
There are no specific dosage recommendations for Mestinon in patients with hepatic impairment.
\*\*Method of administration\*\*
Mestinon should be taken with water. For oral use.4.3 Contraindications
Mestinon is contra-indicated in patients with:
- Hypersensitivity to the active substance, bromides or to any of the excipients listed in section 6.1.
- Mechanical gastro-intestinal or urinary obstruction4.4 Special warnings and precautions for use
Extreme caution is required when administering Mestinon to patients with obstructive respiratory diseases like bronchial asthma and chronic obstructive pulmonary disease (COPD).
Care must be taken in patients with:
- Arrhythmias such as bradycardia and AV block (elderly patients may be more susceptible to dysrhythmias than the young adult)
- Recent coronary occlusion
- Hypotension,
- Vagotonia
- Peptic ulcer
- Epilepsy or Parkinsonism
- Hyperthyroidism
- Renal impairment
When relatively large doses of Mestinon are taken by myasthenic patients it may be necessary to give atropine or other anticholinergic drugs to specifically counteract the muscarinic effects of Mestinon while maintaining its nicotinergic effect.
In all patients the possibility of "cholinergic crisis", due to overdose of Mestinon, and its differentiation from "myasthenic crisis", due to increased severity of the disease, must be considered. Both types of crisis are manifested by increased muscle weakness, but whereas myasthenic crisis may require more intensive anticholinesterase treatment, cholinergic crisis calls for immediate discontinuation of this treatment and appropriate supportive measures, including respiratory assistance.
The requirement for Mestinon is usually markedly decreased after thymectomy or when additional therapy (steroids, immunosuppressant drugs) is given. (see section 4.5).
Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine.4.5 Interaction with other medicinal products and other forms of interaction
\*Immunosuppressant drugs\*
The requirement for pyridostigmine bromide could be decreased by concomitant use with corticosteroids or immunosuppressant drugs. Nethertheless, a new addition of corticosteroids may initially aggravate the symptoms of myasthenia gravis.
\*\*\*Thymectomy\*\*\*
The need for Mestinon dosing may be decreased after thymectomy. (see section 4.4)
\*Methylcellulose\*
Methylcellulose and medicine containing methylcellulose as excipients can completely inhibit absorption of pyridostigmine bromide.
\*Antimuscarinics\*
Atropine and hyoscine antagonise the muscarinic effects of pyridostigmine bromide and the slower gastro-intestinal motility caused by these drugs may affect the absorption of pyridostigmine.
\*Muscle Relaxants\*
Pyridostigmine antagonises the effect of non-depolarising muscle relaxants (e.g. pancuronium and vecuronium). Pyridostigmine may prolong the effect of depolarising muscle relaxants (e.g. suxamethonium).
\*Others\*
Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission may interact with pyridostigmine bromide.4.6 Fertility, pregnancy and lactation
Fertility
Nonclinical investigations in rats have not shown any negative effects on reproductive behaviour.
Pregnancy
The safety of Mestinon during pregnancy has not been established.
Although the possible hazards to mother and child must be weighed against the potential benefits in every case, experience with Mestinon in pregnant patients with myasthenia gravis has revealed no untoward effect of the drug on the course of pregnancy. As the severity of myasthenia gravis often fluctuates considerably in pregnancy, particular care is required to avoid cholinergic crisis due to overdose. Since pyridostigmine bromide crosses the placenta barrier excessive dose of pyridostigmine should be avoided; the newborn child should be monitored to possible effects.
Reproductive studies in rabbits and rats showed no teratogenic but embryo-/foetotoxic effects at doses toxic to the dam (see section 5.3).
Intravenous application of pyridostigmine can induce contraction of the uterus (especially in the last period of pregnancy).
Lactation
The safety of pyridostigmine during lactation has not been established. Observations indicate that only negligible amounts of pyridostigmine are excreted in breast milk. Nevertheless, due regard should be paid to possible effects on the breast-fed infant.4.7 Effects on ability to drive and use machines
Miosis and accommodation disorders caused by pyridostigmine bromide or an inadequate treatment of Myasthenia gravis, Mestinon may impair visual acuity and consequently the ability to react as well as the ability to drive and use machinery.4.8 Undesirable effects
As with all cholinergic products, Mestinon may have unwanted functional effects on the autonomic nervous system. Muscarine-like adverse effects may be exhibited as nausea, vomiting, diarrhoea, abdominal cramps, increased peristaltic and increased bronchial secretion, salivation, bradycardia and miosis.
The primary nicotinic effects are muscle spasms, fasciculation and muscular weakness.
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000) Very rare (<1/10,000) Not known (cannot be estimated from the available data)
The following undesirable effects were observed whereas the frequency of undesirable effect is not known:
\*\*Immune system disorders\*\*
Frequency not known: Drug hypersensitivity
\*\*Nervous system disorders\*\*
Frequency not known: Syncope
\*\*Eye disorders\*\*
Frequency not known: Miosis, increased lacrimation, accommodation disorders (e.g. blurred vision)
\*\*Cardiac disorders\*\*
Frequency not known: Arrhythmia (including bradycardia, tachycardia, AV block), Prinzmetal angina, as well as syncope and hypotension (see section 4.9)
\*\*Vascular disorders\*\*
Frequency not known: Flushing, hypotension
\*\*Respiratory, thoracic and mediastinal disorders\*\*
Frequency not known: Increased bronchial secretion combined with bronchoconstriction
\*\*Gastrointestinal disorders\*\*
Frequency not known: Nausea, vomiting, diarrhoea, gastrointestinal hypermotility, salivary hypersecretion, abdominal symptoms (e.g. discomfort pain, cramps etc.)
\*\*Skin and subcutaneous tissue disorders\*\*
Frequency not known: Rash (disappears usually soon after ceasing of medication. Bromide containing medicines should no longer be used.) Hyperhidrosis, urticaria
\*\*Musculoskeletal and connective tissue disorders\*\*
Frequency not known: Increased muscle weakness fasciculation, tremors and muscle cramps or muscle hypotonia (see section 4.9)
\*\*Renal and urinary disorders\*\*
Frequency not known: Urinary urgency
Because these symptoms may be an indication of cholinergic crisis, the physician should be notified immediately to clarify the diagnosis (see section 4.9)
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard4.9 Overdose
Overdosage may lead to “cholinergic crisis” characterised by severe muscarinic and nicotinic symptoms of marked muscle weakness. Cardiovascular and respiratory failure may occur.
Mestinon may cause cholinergic crisis. Signs of overdosage due to muscarinic effects may include abdominal cramps, increased peristalsis, diarrhoea, nausea and vomiting, increased bronchial secretions, bronchospasm, salivation, hyperhydrosis and miosis. Nicotinic effects consist of muscular cramps, fasciculations and general weakness up to paralysis.
Hypotension up to cardiovascular collapse, bradyarrhythmia, up to cardiac arrest may occur.
Central nervous system effects may include agitation, confusion, slurred speech, nervousness, irritation, visual hallucinations. Convulsions and coma may occur.
Mestinon treatment must be stopped immediately. Artificial ventilation should be instituted if respiration is severely depressed. Atropine sulphate 1 to 2mg intravenously is an antidote to the muscarinic effects. Doses may be repeated every 5 to 30 minutes as needed.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Nervous system, parasympathomimetics, anticholinesterases, pyridostigmine , ATC code: N07AA02
Pyridostigmine is a reversible cholinesterase inhibitor, which an enzyme inactivates acetylcholine. Pyridostigmine prolongs the acetylcholine effect at the synaptic cleft. It does not cross the blood-brain barrier at non-toxic doses. Pyridostigmine has a more prolonged action than neostigmine although it is somewhat slower to take effect (generally taking 30-60 minutes). Because it has a weaker muscarinic effect than neostigmine it is usually much better tolerated by myasthenic patients, in whom its longer duration of action is also an advantage.5.2 Pharmacokinetic properties
Oral pyridostigmine bromide is poorly absorbed by about 22-25%. The rate and extent of absorption show wide inter-individual differences.
Administered in healthy volunteers at oral daily doses of 120 mg, 120-370 mg, and 180-1440 mg, the oral absolute bioavailability of pyridostigmine bromide was 7.6%, 18.9%, and 3-4% with Cmax of 40-80 μg/L, 20-100 μg/L, and 180 μg/L at tmax of 3-4 h, 1.5-6 h, and 1.5 h, respectively. This low and highly variable bioavailability across studies is attributed to the low absorption rate of pyridostigmine. In patients with myasthenia gravis, oral absolute bioavailability may decrease to 3.3%.
Distribution
Pyridostigmine is not bound to plasma proteins. The apparent volume of distribution after intravenous administration was 1.03 L/kg to 1.43 L/kg in healthy subjects, 1.76 L/kg in myasthenia gravis patients, and 0.53 to 1.1 L/kg in surgical patients.
The concentration of pyridostigmine in breast milk has been found to be 36 to 113% compared to maternal plasma, which implies a very low dose to the nursing infant (about 0.1% of the dose per kilogram bodyweight taken by the mother).
Metabolism
Pyridostigmine is metabolized only to a small extent. It is hydrolised by plasma cholinesterases. The main metabolite of pyridostigmine is the hydrolysis product 3-hydroxy-N-methylpyridinium.
Elimination
Systemic (intravenous) pyridostigmine is mainly excreted by the kidneys (75-90%) as parent compound and as inactive metabolites at a ratio of about 4:1. With oral use, a total of 5-15% of oral doses is dose-dependently excreted by the kidneys as parent compound, thus reflecting the low degree of oral pyridostigmine absorption.
The total plasma clearance was very rapid with 0.65 L/h/kg in healthy subjects, 0.29-1.0 L/h/kg in myasthenic patients, and 0.52-0.98 L/h/kg in surgical patients, respectively.
After intravenous administration, the apparent terminal elimination half-life was 1.51-1.74 h in healthy volunteers, 1.05 h in myasthenic patients, and 0.38-1.86 h in surgical patients, respectively. With oral administration, this was 3 to 4 h.5.3 Preclinical safety data
There are no preclinical data of relevance to the prescriber, which are additional to those already included in other sections of the SmPC.
## Pharmaceutical Particulars
6.1 List of excipients
Each tablet contains:
Lactose
Starch
Precipitated Silica
Talc
Magnesium Stearate
Purified Water6.2 Incompatibilities
Not applicable.6.3 Shelf life
3 years.6.4 Special precautions for storage
Store below 25°C. Store in the original package in order to protect from light and moisture.6.5 Nature and contents of container
Amber glass bottles with aluminium screw or low density polyethylene caps and desiccant containing 200 tablets.6.6 Special precautions for disposal and other handling
No special requirements for disposal.
- Company Detail Path
- /organization/mylan-laboratories-limited
